1. Mechanism of RU58841 in Treating Hair Loss
RU58841 is a non-steroidal anti-androgen substance, first developed in the 1980s by researchers seeking androgen-blocking therapies.
What distinguishes RU58841 from other anti-androgen drugs is that it specifically targets the testosterone receptor rather than trying to reduce or block the production of testosterone or DHT (dihydrotestosterone).
RU58841 blocks the interaction between DHT and hair follicle receptors, thereby treating male pattern baldness. In contrast, Finasteride works by inhibiting type II 5α-reductase, reducing the production of DHT, and reversing hair follicle miniaturization to treat hair loss. In terms of mechanism, unlike Finasteride, RU58841 does not activate receptors, which theoretically results in fewer side effects.
2. Research and Development of RU58841
Modern medicine shows that anti-androgens have potential in treating male prostate cancer, acne, and male pattern baldness. Because RU58841 demonstrates abnormally high local activity without systemic activity, the compound has attracted significant attention and research.
Initially, studies on RU58841 for hair loss treatment were mostly conducted in animals.
For example, in a trial titled "Follicular Regrowth in Bald Monkey Scalps with 5α-Reductase Inhibitors (Finasteride) or Androgen Receptor Antagonists (RU58841)", researchers organized three groups of test subjects, each consisting of 10 monkeys.
The first group was given 1mg of Finasteride daily.
The second group received a placebo in the same dosage.
The third group of monkeys was administered either 5% RU58841 (4 monkeys), 0.5% RU58841 (3 monkeys), or a vehicle (3 monkeys).
Results showed:
The monkeys treated with Finasteride saw an 88% increase in hair follicle growth, while those treated with 5% RU58841 saw a 103% increase.
The final hair follicle size in the Finasteride-treated monkeys grew by 12%, while the 5% RU58841 group grew by 26%.
The 0.5% RU58841 showed a slight effect, while the placebo group showed no effect.
Both the Finasteride and RU58841 groups showed varying degrees of hair regrowth.
After just 2 months of treatment, the 5% RU58841 induced the greatest hair growth.
Additionally, three months after discontinuation, two monkeys treated with 5% RU58841 had detectable levels of RU and its metabolites (10-20 ng/ml) in their plasma, with one still detectable after 6 months.
During the treatment, Finasteride reduced serum DHT by approximately 70%, while there was no significant change in the RU58841-treated monkeys.
There are many similar animal model-based studies available in foreign literature. In simple terms, the findings from these studies can be summarized as:
"When we used RU58841 on animals, we found it had good results in treating hair loss!"
The above experiments were all conducted on animals until a company named Prostrakan obtained the rights to RU58841 and renamed it PSK-3841, initiating human studies on its effectiveness in treating androgenic alopecia and acne.
Prostrakan conducted Phase 1 and Phase 2 human clinical trials.
Phase 1 involved 30 participants who applied a 5% RU58841 solution twice daily for 4 weeks. After the second-phase trial, Prostrakan released the following statement:
A very positive conclusion was reached: after six months of treatment with PSK3481, the results were similar to or even better than those achieved with Finasteride treatment!
If you want to buy RU58841 Powder and would like to learn more other products, please feel free to contact Xi'an Ruichi. We look forward to hearing from you.
Email: Jenny@ruichibio.com
Reference:https://www.ruichibio.com/active-pharmaceutical-ingredients/ru58841-powder.html